Google
PHIO — PHIO PHARMACEUTICALS CORP (Healthcare >> Biotechnology)
PHIO FAQ
What is PHIO's ROE?
PHIO PHARMACEUTICALS CORP reports a Return on Equity (ROE) of -66.41%.
What is PHIO's dividend yield?
PHIO PHARMACEUTICALS CORP offers a dividend yield of 0.00%.
What is PHIO's Deepscope Quality Score?
Deepscope rates PHIO's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PHIO?
Deepscope's AI Timing Score for PHIO is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PHIO belong to?
PHIO PHARMACEUTICALS CORP is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.06
Price
-0.08
(-7.02%)
Day Change
|
|
|---|
PHIO, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.06 |
| PBV / Sector |
0.80 / 4.63
GREAT
|
| Earning Per Share | -0.87 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.14 M
GREAT
|
| Average 1W Daily Value |
0.14 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:06 |
| Symbol | PHIO |
| Name | PHIO PHARMACEUTICALS CORP |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 11.62 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 13.24 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 411 Swedeland Road, King of Prussia, PA, United States, 19406
Phone: 610 947 0251
Website: https://phiopharma.com
Sector: Healthcare >> Biotechnology
Description: Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
